|
1
|
American Cancer Society: Cancer facts
& figures. 2015, https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2015/cancer-facts-and-figures-2015.pdf
|
|
2
|
Edwards BK, Noone AM, Mariotto AB, Simard
EP, Boscoe FP, Henley SJ, Jemal A, Cho H, Anderson RN, Kohler BA,
et al: Annual Report to the Nation on the status of cancer,
1975–2010, featuring prevalence of comorbidity and impact on
survival among persons with lung, colorectal, breast, or prostate
cancer. Cancer. 120:1290–1314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015: CA Cancer J Clin. 65:5–29. 2015.
|
|
4
|
Lo-Fo-Wong DN, Sitnikova K, Sprangers MA
and de Haes HC: Predictors of health care use of women with breast
cancer: A systematic review. Breast J. 21:508–513. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rakha EA, El-Sayed ME, Green AR, Lee AH,
Robertson JF and Ellis IO: Prognostic markers in triple-negative
breast cancer. Cancer. 109:25–32. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li H, Wang C, Yu J, Cao S, Wei F, Zhang W,
Han Y and Ren XB: Dendritic cell-activated cytokine-induced killer
cells enhance the anti-tumor effect of chemotherapy on non-small
cell lung cancer in patients after surgery. Cytotherapy.
11:1076–1083. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hui KM: CIK cells-current status, clinical
perspectives and future prospects-the good news. Expert Opin Biol
Ther. 12:659–661. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ma Y, Zhang Z, Tang L, Xu YC, Xie ZM, Gu
XF and Wang HX: Cytokine-induced killer cells in the treatment of
patients with solid carcinomas: A systematic review and pooled
analysis. Cytotherapy. 14:483–493. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang X, Yu W, Li H, Yu J, Zhang X, Ren X
and Cao S: Can the dual-functional capability of CIK cells be used
to improve antitumor effects? Cell Immunol. 287:18–22. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartkova J, Horejsí Z, Koed K, Krämer A,
Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, et
al: DNA damage response as a candidate anti-cancer barrier in early
human tumorigenesis. Nature. 434:864–870. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Harms K, Nozell S and Chen X: The common
and distinct target genes of the p53 family transcription factors.
Cell Mol Life Sci. 61:822–842. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao Y, Chaiswing L, Velez JM,
Batinic-Haberle I, Colburn NH, Oberley TD and St Clair DK: p53
translocation to mitochondria precedes its nuclear translocation
and targets mitochondrial oxidative defense protein-manganese
superoxide dismutase. Cancer Res. 65:3745–3750. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chipuk JE, Kuwana T, Bouchier-Hayes L,
Droin NM, Newmeyer DD, Schuler M and Green DR: Direct activation of
Bax by p53 mediates mitochondrial membrane permeabilization and
apoptosis. Science. 303:1010–1014. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mayo LD and Donner DB: A
phosphatidylinositol 3-kinase/Akt pathway promotes translocation of
Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA.
98:pp. 11598–11603. 2001, View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gottlieb TM, Leal JF, Seger R, Taya Y and
Oren M: Cross-talk between Akt, p53 and Mdm2: Possible implications
for the regulation of apoptosis. Oncogene. 21:1299–1303. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Oren M, Damalas A, Gottlieb T, Michael D,
Taplick J, Leal JF, Maya R, Moas M, Seger R, Taya Y and Ben-Ze'ev
A: Regulation of p53: Intricate loops and delicate balances.
Biochem Pharmacol. 64:865–871. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shtraizent N, Matsui H, Polotskaia A and
Bargonetti J: Hot spot mutation in TP53 (R248Q) causes oncogenic
gain-of-function phenotypes in a breast cancer cell line derived
from an African American patient. Int J Environ Res Public Health.
13:ijerph130100222015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Burgess A, Chia KM, Haupt S, Thomas D,
Haupt Y and Lim E: Clinical Overview of MDM2/X-Targeted Therapies.
Front Oncol. 6:72016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Alsner J, Yilmaz M, Guldberg P, Hansen LL
and Overgaard J: Heterogeneity in the clinical phenotype of TP53
mutations in breast cancer patients. Clin Cancer Res. 6:3923–3931.
2000.PubMed/NCBI
|
|
20
|
Freed-Pastor WA and Prives C: Mutant p53:
One name, many proteins. Genes Dev. 26:1268–1286. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Walerych D, Napoli M, Collavin L and Del
Sal G: The rebel angel: Mutant p53 as the driving oncogene in
breast cancer. Carcinogenesis. 33:2007–2017. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Muller PA and Vousden KH: Mutant p53 in
cancer: New functions and therapeutic opportunities. Cancer Cell.
25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yeudall WA, Vaughan CA, Miyazaki H,
Ramamoorthy M, Choi MY, Chapman CG, Wang H, Black E, Bulysheva AA,
Deb SP, et al: Gain-of-function mutant p53 upregulates CXC
chemokines and enhances cell migration. Carcinogenesis. 33:442–451.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Haupt Y, Maya R, Kazaz A and Oren M: Mdm2
promotes the rapid degradation of p53. Nature. 387:296–299. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bond GL, Hu W and Levine AJ: MDM2 is a
central node in the p53 pathway: 12 years and counting. Curr Cancer
Drug Targets. 5:3–8. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Onel K and Cordon-Cardo C: MDM2 and
prognosis. Mol Cancer Res. 2:1–8. 2004.PubMed/NCBI
|
|
27
|
de Rozieres S, Maya R, Oren M and Lozano
G: The loss of mdm2 induces p53-mediated apoptosis. Oncogene.
19:1691–1697. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Steinman HA, Burstein E, Lengner C,
Gosselin J, Pihan G, Duckett CS and Jones SN: An alternative splice
form of Mdm2 induces p53-independent cell growth and tumorigenesis.
J Biol Chem. 279:4877–4886. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Terzian T, Suh YA, Iwakuma T, Post SM,
Neumann M, Lang GA, Van Pelt CS and Lozano G: The inherent
instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.
Genes Dev. 22:1337–1344. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-delta delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vijayakumaran R, Tan KH, Miranda PJ, Haupt
S and Haupt Y: Regulation of Mutant p53 Protein Expression. Front
Oncol. 5:2842015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vousden KH and Prives C: Blinded by the
light: The growing complexity of p53. Cell. 137:413–431. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kojima K, Konopleva M, Samudio IJ, Schober
WD, Bornmann WG and Andreeff M: Concomitant inhibition of MDM2 and
Bcl-2 protein function synergistically induce mitochondrial
apoptosis in AML. Cell Cycle. 5:2778–2786. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li M, Brooks CL, Wu-Baer F, Chen D, Baer R
and Gu W: Mono-versus polyubiquitination: Differential control of
p53 fate by Mdm2. Science. 302:1972–1975. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shadfan M, Lopez-Pajares V and Yuan ZM:
MDM2 and MDMX: Alone and together in regulation of p53. Transl
Cancer Res. 1:88–89. 2012.PubMed/NCBI
|
|
36
|
Leslie PL, Ke H and Zhang Y: The MDM2 RING
domain and central acidic domain play distinct roles in MDM2
protein homodimerization and MDM2-MDMX protein heterodimerization.
J Biol Chem. 290:12941–12950. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Brooks CL and Gu W: p53 ubiquitination:
Mdm2 and beyond. Mol Cell. 21:307–315. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hoffman Y, Pilpel Y and Oren M: microRNAs
and Alu elements in the p53-Mdm2-Mdm4 regulatory network. J Mol
Cell Biol. 6:192–197. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kamio T, Gu BW, Olson TS, Zhang Y, Mason
PJ and Bessler M: Mice with a Mutation in the Mdm2 gene that
interferes with MDM2/Ribosomal protein binding develop a defect in
Erythropoiesis. PLoS One. 11:e01522632016. View Article : Google Scholar : PubMed/NCBI
|
